Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment

1. Front Matter

   Pages i-xi

   PDF

2. Breast Mucin and Associated Antigens in Diagnosis and Therapy

   • Jerry A. Peterson, Roberto L. Ceriani

   Pages 1-8

3. Peptide Epitopes in Breast Cancer Mucins

   • Pei-Xiang Xing, Vasso Apostolopoulos, Joe Trapani, Julie Prenzoska, Ian F. C. McKenzie

   Pages 9-16

4. Does a Novel form of the Breast Cancer Marker Protein, MUC1, Act as a Receptor Molecule that Modulates Signal Transduction?

   • Daniel H. Wreschner, Sheila Zrihan-Licht, Amos Baruch, Dalit Sagiv, Mor-li Hartman, Nechama Smorodinsky et al.

   Pages 17-26

5. Cancer Metastasis Determined by Carbohydrate-Mediated Cell Adhesion

   • Tatsuro Irimura

   Pages 27-34

6. Experimental Immunotherapy of Breast Cancer Using Alpha Interferon Conjugated to Monoclonal Antibody Mc5

   • Luciano Ozzello, Carolyn M. De Rosa, David V. Habif Sr., Edward W. Blank, Roberto L. Ceriani, Kari Cantell

   Pages 35-46

7. Circulating and Tissue Markers in the Longitudinal Management of Breast Cancer Patients

   • Morton K. Schwartz

   Pages 47-53

8. Engineering of Antibodies for Breast Cancer Therapy: Construction of Chimeric and Humanized Versions of the Murine Monoclonal Antibody BrE-3

   • Joseph R. Couto, Edward W. Blank, Jerry A. Peterson, Radwan Kiwan, Roberto L. Ceriani, Eduardo A. Padlan

   Pages 55-59

9. Humanization of an Anti-Mucin Antibody for Breast and Ovarian Cancer Therapy

   • T. S. Baker, H. M. Caskey-Finney, D. J. King, A. D. G. Lawson, A. Lyons, A. Mountain et al.

   Pages 61-82

10. Towards an Immunotherapy for p185HER2 Overexpressing Tumors

    • Paul Carter, Maria L. Rodrigues, Gail D. Lewis, Irene Figari, M. Refaat Shalaby

    Pages 83-94

11. Branching N-Linked Oligosaccharides in Breast Cancer

    • James W. Dennis, Bernard Fernandez, Bozena Korczak, Paul Goss, Michael Baker

    Pages 95-104

12. Specificity of the IgG Response in Mice and Human Breast Cancer Patients Following Immunization Against Synthetic Sialyl-Tn, An Epitope with Possible Functional Significance in Metastasis

    • B. Michael Longenecker, Mark Reddish, Rao Koganty, Grant D. MacLean

    Pages 105-124

13. Vaccination Against Breast Cancer — Studies in an Animal Model

    • Nechama I. Smorodinsky, Ronit Yarden, Lior Carmon, Daniel H. Wreschner, Iafa Keydar, Mara Hareuveni

    Pages 125-137

14. Anti-Idiotype Antibodies as Potential Therapeutic Agents for Human Breast Cancer

    • Malaya Bhattacharya-Chatterjee, Ewe Mrozek, Sonjoy Mukerjee, Roberto L. Ceriani, Heinz Kohler, Kenneth A. Foon

    Pages 139-148

15. The Simultaneous Expression of c-erbB-2 Oncoprotein and Laminin Receptor on Primary Breast Tumors has a Predicting Potential Analogous to that of The Lymph Node Status

    • Maria I. Colnaghi

    Pages 149-154

16. Multivariate Prognostic Model for Infiltrating Ductal Carcinoma of the Breast in the Axillary Node-Free Patient

    • Roberto L. Ceriani, Frank Baratta, Ramon J. Gaslonde, Carolyn M. De Rosa, Luciano Ozzello

    Pages 155-167

17. The Use of Monoclonal Antibody Immunoconjugates in Cancer Therapy

    • Geoffrey A. Pietersz, Kenia Krauer, Ian F. C. McKenzie

    Pages 169-179

18. Radioimmunolocalization of Breast Cancer Using BrE-3 Monoclonal Antibody

    • Elissa L. Kramer, Sally J. DeNardo, Leonard Liebes, Marilyn E. Noz, Linda Kroger, Stephan D. Glenn et al.

    Pages 181-192

19. Suppression of Human Anti-Mouse Antibody Response to Murine Monoclonal Antibody L6 by Deoxyspergualin: A Phase I Study

    • Kapil Dhingra, Daniel Booser, Aman Buzdar, Martin Raber, Lia Gutierrez, Gabriel Hortobagyi et al.

    Pages 193-202

20. Overview of Radioimmunotherapy in Advanced Breast Cancer Using I-131 Chimeric L6

    • S J. DeNardo, L. F. O’Grady, C. M. Richman, G. L. DeNardo

    Pages 203-211

Today, advances in the area of immunology and breast cancer are made at an increasing rate, yielding an amount of information that can become unwieldy. The opportunity for scientists in this area of research to gather together to exchange results and working hypotheses represents, in my belief, a very attractive proposition. With this in mind, these workshops have been convened with two year intervals for the last ten years. In each of them, selected topics have been highlighted. The present workshop underscores the large advancements made in the molecular biology of both breast cancer associated antigens and their corresponding antibodies. Understanding the genetic information for the expression of these antigens has been recently advanced leading to preparation of molecularly engineered reagents for use in vaccination, serum assays, and immunizations for novel antibody production. In the anti-breast cancer antibody field the availability of molecular engineering approaches to humanize murine antibodies has induced intense interest in the creation of less immunogenic antibody forms that are now available for clinical testing. Clinical studies using anti-breast murine antibody continue to be carried out and are presented at this meeting establishing a base line for safety and efficaciousness in imaging and immunotherapy that it is hoped will be superseded by the humanized forms. Basic immunology and immunochemistry studies in breast cancer are also included in this workshop that demonstrate the fast pace at which this research is advancing in many laboratories worldwide.

• Antigen
• Expression
• base
• chemistry
• imaging
• preparation

• Cancer Research Fund of Contra Costa, Walnut Creek, USA

  Roberto L. Ceriani

Policies and ethics